[4-[1-(Oxetan-3-yl)piperidin-4-yl]sulfonylphenyl]methanamine | 1450723-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-[1-(Oxetan-3-yl)piperidin-4-yl]sulfonylphenyl]methanamine
• 英文别名: [4-[1-(oxetan-3-yl)piperidin-4-yl]sulfonylphenyl]methanamine
• CAS: 1450723-85-9
• 化学式: C₁₅H₂₂N₂O₃S
• 分子量: 310.417
• InChiKey: LOLBGKXWYSXULS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  81
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [4-[1-(Oxetan-3-yl)piperidin-4-yl]sulfonylphenyl]methanamine 以 乙醇 、 甲苯 为溶剂， 反应 4.0h， 生成 N-[[4-[[1-(oxetan-3-yl)-4-piperidyl]suIfonyl]phenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide
  参考文献：
  名称：

  Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

  摘要：

  Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea and amide-containing NAMPT inhibitors. An optimized 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived compound exhibited potent anti-NAMPT activity (18; BC NAMPT IC50 = 11 nM; PC-3 antiproliferative IC50 = 36 nM), satisfactory mouse PK properties, and was efficacious in a PC-3 mouse xenograft model. The crystal structure of another optimized compound (29; NAMPT IC50 = 10 nM; A2780 antiproliferative IC50 = 7 nM) in complex with the NAMPT protein was also determined. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.090
• 作为产物：
  描述：

  4-(4-氰基苯磺酰基)-哌啶-1-羧酸叔丁酯 在 titanium(IV) tetraethanolate 、 氨 、 氢气 、 sodium cyanoborohydride 、 三氟乙酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 18.0h， 生成 [4-[1-(Oxetan-3-yl)piperidin-4-yl]sulfonylphenyl]methanamine
  参考文献：
  名称：

  Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

  摘要：

  Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea and amide-containing NAMPT inhibitors. An optimized 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived compound exhibited potent anti-NAMPT activity (18; BC NAMPT IC50 = 11 nM; PC-3 antiproliferative IC50 = 36 nM), satisfactory mouse PK properties, and was efficacious in a PC-3 mouse xenograft model. The crystal structure of another optimized compound (29; NAMPT IC50 = 10 nM; A2780 antiproliferative IC50 = 7 nM) in complex with the NAMPT protein was also determined. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.090

文献信息

• Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility
  作者：Mark Zak、Bianca M. Liederer、Deepak Sampath、Po-wai Yuen、Kenneth W. Bair、Timm Baumeister、Alexandre J. Buckmelter、Karl H. Clodfelter、Eric Cheng、Lisa Crocker、Bang Fu、Bingsong Han、Guangkun Li、Yen-Ching Ho、Jian Lin、Xiongcai Liu、Justin Ly、Thomas O’Brien、Dominic J. Reynolds、Nicholas Skelton、Chase C. Smith、Suzanne Tay、Weiru Wang、Zhongguo Wang、Yang Xiao、Lei Zhang、Guiling Zhao、Xiaozhang Zheng、Peter S. Dragovich

  DOI：10.1016/j.bmcl.2014.12.026

  日期：2015.2

  Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likely source of the TDI signal, and replacement with other bicyclic systems was found to reduce or eliminate the TDI finding. A strategy of reducing the number of aromatic rings and/or lowering cLogD(7.4) was then employed to significantly improve aqueous solubility. These efforts culminated in the discovery of 42, a compound with no evidence of TDI, improved aqueous solubility, and robust efficacy in tumor xenograft studies. (C) 2014 Elsevier Ltd. All rights reserved.